1. European Commission, Commission Regulation (EU) 2019/698 of 30 April 2019 amending Annexes III and V to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products, http://data.europa.eu/eli/reg/2019/698/oj (accessed 24 September 2020).
2. SCCP (Scientific Committee on Consumer Products), Opinion on Climbazole (COLIPA no P64), 20 September 2005, SCCP/0918/05, https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_027.pdf (accessed 14 December 2020).
3. Topical delivery of climbazole to mammalian skin;Paz-Alvarez;Int. J. Pharm.,2018
4. W. Ritter, Pharmakokinetik von Climbazol, internal report (unpublished), Bayer AG, Institut für Klinische Pharmakologie, Wuppertal (Germany), 2 October 1984.
5. J. Larner, R. French, Climbazole Toxicokinetic Review, internal report (unpublished), Inveresk Research, Tranent (Scotland). Sponsor: Haarmann & Reimer GmbH, Holzminden. Project no. 470316, 3 February 2003.